With many years of experience in glycoengineering, CD BioGlyco has solved various shortcomings of the expression systems and brought customers high-quality cell lines to produce glycoproteins. We have confidence to be your essential research assistant in the field of glycobiology.
Most secreted proteins in eukaryotes are glycosylated, and after many common biosynthetic steps, glycan structures mature in a species-dependent manner. Therefore, human therapeutic proteins produced in plants usually contain plant-like rather than human-like glycans, which will affect the biological function, stability and immunogenicity of the protein. The glycoengineering of plant-based expression systems started as a strategy to eliminate plant-like glycans and produce human proteins with compatible glycan structures. Since there are no pathways to synthesize sialylated proteins and the necessary precursors, the precise replication of human glycans is relatively difficult in plants, but it can now be achieved through the cooperative expression of multiple human enzymes.
Although many studies have been devoted to removing plant glycans and replacing them with human counterparts, the presence of plant glycans on proteins can also bring advantages, such as enhancing the immunogenicity of certain vaccines and promoting the interactions between therapeutic proteins and their receptors. At present, the bio-manufacturing of plant-based proteins is still a relatively new method, with only a small number of commercial-scale facilities. But compared with mammalian cell expression systems, it can reduce capital investment and commodity costs by about 50%, and relatively simple plant expression systems are more likely to produce homogenous glycoform, while mammalian expression hosts are more difficult to achieve this goal due to their complex endogenous glycosylation mechanisms.
Fig 1. Typical structures of native mammalian and plant glycans (Fischer, R.; et al. 2018)
CD BioGlyco has put great efforts into exploring the glycoengineered N. benthamiana-based expression system to express different proteins. The services we provide include but are not limited to the following aspects.
CD BioGlyco can customize plant-based glycoprotein expression solutions for customers according to their needs, which not only saves you time, but also saves costs while maintaining high efficiency.
Customers can contact our employees directly and we will respond promptly. If you are interested in our services, please contact us for more detailed information.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.